-
Bi-Lo expands prescription program through loyalty card
GREENVILLE, S.C. — Bi-Lo on Wednesday launched in all of its pharmacies a prescription program that significantly enhances the offerings of its existing program. The expanded program runs through the Bi-Lo BonusCard and offers deep discounts on more than 450 generic medications and varied discounts on name-brand and other generic medication.
-
FDA gives breakthrough therapy designations to experimental cancer drug
RARITAN, N.J. — The Food and Drug Administration has given a special designation to a cancer drug under development by Johnson & Johnson and Pharmacyclics, the companies said.
J&J subsidiary Janssen Research & Development and Pharmacyclics announced that the FDA had given breakthrough therapy designations to the experimental drug ibrutinib as a standalone therapy for relapsed or refractory mantle cell lymphoma in patients who have received prior therapy and for Waldenstrom's macroglobulinemia.